pipette
ESEspañol

An agent-based model of Epstein-Barr virus transmission and vaccination

B. Amoako, Z. Huang, E. W. Thommes, W. Hare, M. G. Cojocaru

PreprintReal-world use

In the authors' words

Epstein- Barr virus (EBV) infects over 90% of adults worldwide, causing infectious mononucleosis (IM) in adolescents and young adults and contributing to multiple malignancies. Despite its global burden, population- level transmission modeling of EBV remains limited. We present the first population- level agent-based model (ABM) of EBV transmission. The model is implemented with 10,000 agents and calibrated to age-specific seroprevalence data from the US National Health and Nutrition Examination Survey. Two complementary calibration methods are evaluated, each with its own distinct advantages: Approximate Bayesian Computation (ABC) and Bayesian Optimization with Expected Quantile Improvement (BO- EQI). ABC directly yields an approximate distribution of transmission parameters for propagation through vaccination scenarios. BO- EQI uses a limited simulation budget to identify well-fitting parameter vectors, particularly as the number of fitted parameters increases. We estimate parameter uncertainty at each resolution in a separate Gaussian-kernel posterior analysis, which requires additional simulations and an explicit model for discrepancies between simulated and observed prevalence. As an illustrative application, we simulate the population-level effect of hypothetical EBV vaccines over a 100-year projection horizon. Similar to a previous modeling study, our results suggest that vaccine durability is at least as critical as efficacy, and that a vaccine with direct protection against only EBV may persistently shift IM burden to older ages, an effect our longer simulation horizon reveals to be a durable equilibrium shift rather than a transient cohort phenomenon. These findings highlight the importance of careful vaccine target product profile design; in particular, our results suggest that dual efficacy against both EBV infection and IM progression represents the most promising achievable target profile, and should be a core design objective for next-generation EBV vaccines.

Main resultThe abstract does not state a limitation.

Appeared: Friday, November 13. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.10.26367734